Live feed08:30:00·31dPRReleasevia QuantisnowAllogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell LymphomaByQuantisnow·Wall Street's wire, on your screen.ALLO· Allogene Therapeutics Inc.Health Care
